Resisting resistance

ApoGen's APOBEC3B inhibitors could keep cancer therapies working longer

While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer therapies.

"As far as we know, we're the only ones that are targeting the underlying mechanisms that cause genomic mutations in tumors," said Thong Le, CEO of Seattle-based incubator Accelerator Corp. ApoGen operates virtually and is managed

Read the full 720 word article

How to gain access

Continue reading with a
two-week free trial.